• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women with ADHD have to make a difficult choice about whether to continue or stop taking ADHD medication during pregnancy and breastfeeding. Little data exists about how long-term exposure to these medications can affect the foetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological disorders such as hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge the need for more high-quality studies.

Risk/Benefit Analysis

Pregnant women who take ADHD medications must weigh the advantages of taking them against potential risks to the fetus. Doctors don't have the information needed to give clear guidelines but they can provide information on benefits and risks that can help pregnant women make informed choices.

A study published in Molecular Psychiatry concluded that women who took ADHD medication in early pregnancy did not have a higher risk of fetal malformations or structural birth defects. Researchers used a large population-based case control study to examine the prevalence of structural defects that were major in infants born to mothers who took stimulants during pregnancy. Pediatric cardiologists, clinical geneticists and other experts looked best over the counter adhd medication for adults - https://www.youtube.com/ - the cases to confirm that the classification was accurate and to eliminate any bias.

However, the researchers' study had its limitations. Researchers were unable to, in the first place to distinguish the effects caused by the medication from the disorder. This makes it difficult for researchers to determine whether the small associations observed among the exposed groups were due to medication use, or if they were caused by comorbidities. The researchers also did not examine long-term outcomes for the offspring.

The study revealed that infants whose mothers took ADHD medication during pregnancy had a higher chance of being admitted to the neonatal care unit (NICU) as compared to mothers who did not use any medication during pregnancy or discontinued taking their medication prior to or during pregnancy. The reason for this was central nervous system disorders. The increased risk of admission was not affected by the stimulant medication that was used during pregnancy.

Women who took stimulant ADHD medications during pregnancy also had a higher risk of having to have a caesarean section or a baby that scored low on the Apgar scale (less than 7). These increases did appear to be unrelated to the type of medication taken during pregnancy.

The research suggests that the small risk associated with the use of ADHD medications during early pregnancy may be offset by the higher benefit to both the mother and child from continued treatment for the woman's condition. Physicians should talk to their patients about this and, if possible, help them improve coping skills which could reduce the effects of her disorder on her daily functioning and her relationships.

Medication Interactions

As more women than ever before are being diagnosed with ADHD and treated with medication, the issue of whether or not to end treatment during pregnancy is a question that doctors are having to confront. Most of the time, these decisions are made in the absence of any evidence that is clear and definitive either way, so physicians must weigh what they know from their own experiences, those of other doctors, and what research says on the topic, along with their own judgments for each individual patient.

Particularly, the issue of potential risks to the infant can be difficult. The research on this subject is based on observation rather than controlled studies, and many of the findings are conflicting. Furthermore, most studies restrict their analysis to live births, which adhd medication is the best may undervalue the serious teratogenic effects that can cause abortion or termination of the pregnancy. The study discussed in the journal club addresses these issues, by examining both information on deceased and live births.

The conclusion is that while some studies have shown a positive association between ADHD medications and the risk of certain birth defects, other studies have found no connection bipolar and adhd medication the majority of studies show a neutral or even slight negative effect. As a result, a careful risk/benefit assessment must be done in each instance.

It can be difficult, if not impossible for women suffering from ADHD to stop taking their medication. In a recent article published in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can lead to depression and feelings of isolation. A loss of medication may also impact the ability to drive safely and perform work-related tasks, which are essential aspects of daily life for people with ADHD.

She suggests women who are uncertain about whether to keep or discontinue medication due to their pregnancy, consider informing family members, friends, and coworkers on the condition, its effects on daily functioning, and the advantages of continuing the current treatment plan. It can also help the woman feel supported as she struggles with her decision. Certain medications can pass through the placenta. If a woman decides to not take her ADHD medication while breastfeeding, it's important to be aware that the drug could be transferred to the baby.

Risk of Birth Defects

As the use and abuse of ADHD medications to treat the symptoms of attention deficit hyperactivity disorder (ADHD) is increasing, so does concern about the potential adverse effects of the drugs on fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge regarding this issue. Using two massive data sets, researchers were able to examine more than 4.3 million pregnancies to determine whether the use of stimulant medications increased the risk of birth defects. Researchers discovered that, while the risk overall is low, first-trimester ADHD medication use was associated with slightly higher rates of certain heart defects, like ventriculoseptal defect.

The researchers of the study did not find any association between early use of medication and other congenital anomalies like facial deformities, or club feet. The results are in line with previous studies that showed a small, but significant increase in the number of cardiac malformations among women who began taking ADHD medication prior to the time of the birth of their child. This risk increased during the latter stages of pregnancy when a large number of women decided to stop taking their medication.

Women who were taking ADHD medication during the first trimester were more likely require a caesarean delivery, have a low Apgar after delivery, and had a baby that required breathing assistance at birth. The authors of the study were unable to remove bias in selection since they limited their study to women with no other medical conditions that might have contributed to the findings.

The researchers hope their research will aid in the clinical decisions of doctors who treat pregnant women. They suggest that although the discussion of the benefits and risks is important however, the decision to stop or continue medication should be based on the woman's requirements and the severity of her ADHD symptoms.

The authors also caution that while discontinuing the medications is an option, it is not a recommended practice because of the high prevalence of depression and other mental health problems in women who are pregnant or post-partum. Further, the research suggests that women who choose to stop taking their medication are more likely to experience a difficult time adjusting to life without them after the birth of their baby.

Nursing

The responsibilities of a new mom can be overwhelming. Women with ADHD can face severe challenges when they have to manage their symptoms, attend doctor appointments and prepare for the birth of a baby and adjust to a new routine. Therefore, many women decide to continue taking their ADHD medications used for adhd throughout pregnancy.

The majority of stimulant medicines are absorbed through breast milk in very small amounts, therefore the risk to the infant who is breastfeeding is low. The amount of exposure to medications will vary based on the dosage the medication is administered, its frequency and the time of day. Additionally, different medications enter the baby’s system via the gastrointestinal tract or breast milk. The impact on the health of a newborn isn't fully comprehended.

Due to the absence of research, some doctors might be tempted to stop taking stimulant medication during a woman's pregnancy. It's a difficult choice for the woman who must weigh the advantages of taking her medication as well as the risk to the foetus. In the meantime, until more information is available, GPs can inquire about pregnant patients whether they have an background of ADHD or if they intend to take medication during the perinatal phase.

Many studies have shown that women can continue taking their ADHD medication safely while breastfeeding and during pregnancy. In the end, many patients are choosing to do so and, in consultation with their doctor they have found that the benefits of keeping their current medication exceed any risk.

Women who suffer from ADHD who are planning to breastfeed should seek advice from a specialist psychiatrist prior to becoming pregnant. They should discuss their medication with their doctor and discuss the pros and cons of continuing treatment. This includes non-pharmacological strategies. Psychoeducation is also required to help pregnant women suffering from ADHD understand their symptoms and underlying disorder Learn about the available treatments and to reinforce existing strategies for managing. This should involve a multidisciplinary approach with the GP, obstetricians and psychiatry. Pregnancy counseling should consist of a discussion of a treatment plan for the mother as well as the child, as well as monitoring for signs of deterioration, and, if needed, adjustments to the medication regimen.